echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Innovent's 2 bispecific antibodies were approved for clinical use

    Innovent's 2 bispecific antibodies were approved for clinical use

    • Last Update: 2021-10-23
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Text|Pharmaceutical Mission Hills

    On September 14, the Center for Drug Evaluation (CDE) of the National Food and Drug Administration of China announced that the two new class 1 biological drugs declared by Cinda Biologics have been approved for clinical use, namely the CD3/Claudin 18.


    Screenshot source: CDE official website

    According to public information, bispecific antibodies are one of Cinda's key research and development areas


    Bispecific antibody therapy is another way to use T cells in the patient's immune system to kill tumors


    (1) IBI389: CD3/Claudin 18.


    It is reported that IBI389 is a bispecific antibody that can simultaneously target CD3 and Claudin 18.


    Claudin protein is a tight junction (tight junction) molecule, and its function is mainly to adjust the permeability of the barrier structure


    However, studies have found that Claudin 18.


    (2) IBI322: CD47/PD-L1 bispecific antibody

    Public information shows that IBI322 is a potential "first-in-class" recombinant anti-CD47/PD-L1 bispecific antibody developed by Cinda.


    CD47 (recombinant fully human anti-differentiation antigen cluster 47) protein is an immunomodulatory molecule overexpressed on cancer cells.


    By targeting the two pathways of CD47 and PD-L1, IBI322 is expected to enhance the body's ability to kill tumor cells


    According to the announcement issued by Cinda Biologics, the product is a molecule with "first-in-class" potential, which is more compatible with tumor tissues, thereby reducing the toxicity of the target to normal tissues and delaying the occurrence of drug resistance.


    In addition to the two products, bio-letter bispecific antibody product line further comprises an anti-PD-1 / PD-L1 double-antibody IBI318, anti-PD-1 / HER2 double antibody IBI315 the like


    Reference materials:

    [1] Center for Drug Evaluation of China National Medical Products Administration.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.